Article
Microbiology
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Aminah Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Yazed Saleh Alsowaida
Summary: This study aimed to compare the effectiveness and safety of C-T and CAZ-AVI in treating infections caused by resistant P. aeruginosa. The results showed no significant differences between C-T and CAZ-AVI in terms of in-hospital mortality, 30-day mortality, clinical cure, and safety. Both drugs can be potential options for the treatment of MDR P. aeruginosa infections.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Microbiology
Yiwei Zhu, Jie Chen, Han Shen, Zhongju Chen, Qi-Wen Yang, Jin Zhu, Xi Li, Qing Yang, Feng Zhao, Jingshu Ji, Heng Cai, Yue Li, Linghong Zhang, Sebastian Leptihn, Xiaoting Hua, Yunsong Yu
Summary: Klebsiella pneumoniae carbapenemase (KPC)-producing Pseudomonas aeruginosa (KPC-PA) strains were found in 40.4% of carbapenem-resistant P. aeruginosa (CRPA) isolates, with half of them resistant to ceftazidime-avibactam (CAZ-AVI). Eight plasmid types and two mobile genetic elements mediating bla(KPC-2) transmission were identified through sequencing. Curing bla(KPC-2) plasmids in 28 strains restored CAZ-AVI susceptibility, indicating its role in resistance.
Article
Microbiology
C. Weber, T. Schultze, S. Goettig, J. Kessel, A. Schroeder, M. Tietgen, S. Besier, T. Burbach, S. Haeussler, T. A. Wichelhaus, D. Hack, V. A. J. Kempf, M. Hogardt
Summary: The study demonstrates that cefiderocol is the most effective antipseudomonal beta-lactam agent for multidrug-resistant (MDR) Pseudomonas aeruginosa, with susceptibility rates of 46.6%, 48.4%, and 97.3% for ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol, respectively. The most prevalent sequence type was ST235 (24.7%), followed by ST244, ST175, and ST233, all of which belong to the top 10 high-risk clones with worldwide distribution. Surveillance studies should pay special attention to MDR and highly virulent VIM- and ExoU-producing variants of ST235. Cefiderocol is the preferred treatment option for infections caused by carbapenemase-producing MDR P. aeruginosa, and it has shown favorable outcomes in complicated urinary tract infections and hospital-acquired pneumonia.
MICROBIOLOGY SPECTRUM
(2022)
Article
Infectious Diseases
Helio S. Sader, Cecilia G. Carvalhaes, Jennifer M. Streit, Timothy B. Doyle, Mariana Castanheira
Summary: This study evaluated the in vitro activity of ceftazidime-avibactam and ceftolozane-tazobactam against Pseudomonas aeruginosa and Klebsiella pneumoniae isolates, showing high susceptibility rates for these two drugs. However, limited activity was observed against ESBL and carbapenemase producers in Klebsiella pneumoniae.
MICROBIAL DRUG RESISTANCE
(2021)
Article
Microbiology
Yang Yang, Yan Guo, Dandan Yin, Yonggui Zheng, Shi Wu, Demei Zhu, Fupin Hu
Summary: The study found that cefepime-zidebactam exhibited potent activity against almost all Enterobacterales and good activity against P. aeruginosa, while ceftazidime-avibactam showed good in vitro activity against Enterobacterales and P. aeruginosa but less activity against Acinetobacter baumannii. Most of the carbapenem-resistant Enterobacteriaceae isolates were susceptible to cefepime-zidebactam and ceftazidime-avibactam showed good activity against bla(KPC-2)-positive Enterobacterales and carbapenem-resistant P. aeruginosa.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Infectious Diseases
Helio S. Sader, Mariana Castanheira, Leonard R. Duncan, Rodrigo E. Mendes
Summary: This study evaluated the in vitro activity of four new generation beta-lactam/beta-lactamase inhibitor combinations against P. aeruginosa isolates from patients with skin and soft tissue infections worldwide. The results demonstrated potent activity and broad coverage of these recently approved drugs against contemporary P. aeruginosa isolates.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Microbiology
Michael Marner, Laura Kolberg, Julia Horst, Nils Boehringer, Johannes Huebner, I. Dewa M. Kresna, Yang Liu, Ute Mettal, Lei Wang, Melanie Meyer-Buehn, Sanja Mihajlovic, Matthias Kappler, Till F. Schaeberle, Ulrich von Both
Summary: Antimicrobial resistance poses an increasing threat to healthcare. To address the need for innovative treatment of respiratory infections, antibiotics with new modes of action need to be developed. This study generated the antibiogram of clinical isolates from cystic fibrosis patients and identified bicyclic heptapeptides that inhibit the outer membrane protein BamA, showing strong activity against multidrug-resistant strains.
MICROBIOLOGY SPECTRUM
(2023)
Article
Microbiology
Alba Ruedas-Lopez, Isaac Alonso-Garcia, Cristina Lasarte-Monterrubio, Paula Guijarro-Sanchez, Eva Gato, Juan Carlos Vazquez-Ucha, Juan Andres Vallejo, Pablo Arturo Fraile-Ribot, Begona Fernandez-Perez, David Velasco, Jose Maria Gutierrez-Urbon, Marina Oviano, Alejandro Beceiro, Concepcion Gonzalez-Bello, Antonio Oliver, Jorge Arca-Suarez, German Bou
Summary: This study aimed to analyze the resistance mechanisms of ceftolozane-tazobactam and ceftazidime-avibactam in multidrug-resistant or extensively drug-resistant P. aeruginosa isolates. The findings revealed that most of the resistant isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Chromosomal mutations and specific gene substitutions were identified as the main resistance mechanisms. The study emphasized the potential selection of MDR/XDR P. aeruginosa strains producing certain variants or metallo-beta-lactamases by cephalosporin/beta-lactamase inhibitors, and encouraged judicious use of these agents.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Pharmacology & Pharmacy
Maria Jose Contreras-Gomez, Jose R. W. Martinez, Lina Rivas, Roberto Riquelme-Neira, Juan A. Ugalde, Aniela Wozniak, Patricia Garcia, Jose M. Munita, Jorge Olivares-Pacheco, Manuel Alcalde-Rico
Summary: Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a pathogen that urgently requires new drugs and control methods. Combining beta-lactam drugs with beta-lactamase inhibitors is the primary strategy against this bacterium. This study found that RND efflux pumps play a role in the susceptibility of CRPA to certain combination antibiotics.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Microbiology
Diego Faccone, Juan M. de Mendieta, Ezequiel Albornoz, Magali Chavez, Fabiana Genero, Mariano Echegorry, Paola Ceriana, Andrea Mora, Christine Seah, Alejandra Corso, Roberto G. Melano, Fernando Pasteran
Summary: A ceftazidime-avibactam-resistant KPC-producing Pseudomonas aeruginosa strain, belonging to the high-risk clone ST235/O11, was identified in Argentina. Whole-genome sequencing revealed a D179Y substitution in the Omega loop of KPC-3, corresponding to KPC-31 integrated at the chromosome. Most commonly used carbapenemase detection assays failed to identify the isolate as a KPC producer.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Article
Infectious Diseases
Yu-Lin Lee, Wen-Chien Ko, Po-Ren Hsueh
Summary: This study aimed to investigate the susceptibility and β-lactamase-encoding genes of Pseudomonas aeruginosa isolates with discrepant resistance to different carbapenems. Data on P. aeruginosa isolates from 2012-2021 were analyzed, and minimum inhibitory concentrations were determined. β-lactamase-encoding genes were identified using multiplex polymerase chain reaction assays. The results showed that imipenem-resistant P. aeruginosa isolates had different susceptibility profiles and fewer carbapenemase genes compared to meropenem-resistant or doripenem-resistant isolates. Ceftazidime-avibactam and ceftolozane-tazobactam had higher susceptibility rates than meropenem-vaborbactam for meropenem-resistant P. aeruginosa. These findings are important for resistance trend monitoring and accurate antimicrobial treatment.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Immunology
Yingyi Guo, Ningjing Liu, Zhiwei Lin, Xiaoliang Ba, Chuyue Zhuo, Feifeng Li, Jiong Wang, Yitan Li, Likang Yao, Baomo Liu, Shunian Xiao, Ying Jiang, Chao Zhuo
Summary: This study identified a novel mechanism of CAZ-AVI resistance associated with mutations in the porin LamB in KPC-Kp strains.
EMERGING MICROBES & INFECTIONS
(2021)
Article
Infectious Diseases
Qing Yang, Yue Li, Li Fang, Tailong Lei, Heng Cai, Xiaoting Hua, Min Zheng, Yunsong Yu
Summary: This study characterized a novel KPC-113 variant in a clinical Pseudomonas aeruginosa isolate R20-14. Genomic analysis revealed a plasmid carrying blaKPC-113, which conferred both carbapenem and ceftazidime-avibactam resistance. KPC-113 presented reduced catalytic ability and poor response to avibactam inhibition compared to KPC-2. Efforts should be made to prevent the horizontal spread of blaKPC-113 in clinical settings.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Microbiology
James A. Karlowsky, Sibylle H. Lob, C. Andrew DeRyke, David W. Hilbert, Michael T. Wong, Katherine Young, Fakhar Siddiqui, Mary R. Motyl, Daniel F. Sahm
Summary: The study evaluated the susceptibility of P. aeruginosa strains isolated from patients in the United States to C/T, IMR, and CZA. The results showed that most isolates were susceptible to C/T, and IMR demonstrated greater activity against C/T-nonsusceptible strains compared to CZA.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2022)
Review
Infectious Diseases
Marianna Meschiari, Iacopo Franconi, Erica Bacca, Vincenzo Bianco, Gabriella Orlando, Gianluca Cuomo, Andrea Bedini, Cristina Mussini
Summary: This study reported three cases of post-neurosurgical infections caused by XDR-PA successfully treated with new antibiotics, BLBLIs. The use of C/T and CZA showed promising results in conservative treatment of meningitis and osteomyelitis, indicating potential as complementary therapy options against hard-to-treat P. aeruginosa infections. Further real-life studies are needed to validate these findings.
Article
Infectious Diseases
Naoki Kohira, Meredith A. Hackel, Merime Oota, Miki Takemura, Fupin Hu, Hiromichi Mizuno, Daniel F. Sahm, Yoshinori Yamano
Summary: This study reported the in vitro activity of Cefiderocol (CFDC) and other antibiotics against 1738 clinical isolates of Gram-negative bacilli provided by five medical centres in five provinces of China in 2020. The results showed that CFDC had high susceptibility rates against Pseudomonas aeruginosa and Acinetobacter Spp., but had considerable differences in susceptibility against different types of Enterobacterales isolates. In general, CFDC demonstrated potent in vitro activity against recent clinical isolates obtained from medical centres in mainland China.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE
(2023)
Article
Microbiology
Renru Han, Siquan Shen, Dandan Yin, Li Ding, Qingyu Shi, Yang Yang, Yan Guo, Shi Wu, Peiyuan Zhi, Demei Zhu, Fupin Hu
Summary: Multidrug-resistant Enterobacterales and P. aeruginosa strains are a global public threat. Ceftazidime-avibactam has shown excellent in vitro activity against these strains. In this study, the performance of ceftazidime-avibactam disk diffusion tests was evaluated, and it was found that the 10/4μg concentration showed superior performance and was more suitable for assessing susceptibility.
MICROBIOLOGY SPECTRUM
(2023)
Article
Infectious Diseases
Qin Zhang, Shi Wu, Peipei Song, Yi Liu, Li Ding, Qingyu Shi, Xuan Zhu, Liyuan Zhang, Jun Zhang, Qin Wang, Jian Xu, Fupin Hu
Summary: This study investigated the antibiotic resistance and resistance mechanism of Corynebacterium kroppenstedtii (C. kroppenstedtii) isolated from patients with mastadenitis. A total of 90 C. kroppenstedtii clinical isolates were obtained from clinical specimens in 2018-2019. Antimicrobial susceptibility testing indicated high resistance rates to erythromycin, clindamycin, ciprofloxacin, tetracycline, and trimethoprim-sulfamethoxazole. Resistance genes for specific antibiotics were detected through PCR and DNA sequencing. Amino acid mutations were observed in the gyrA gene among ciprofloxacin-resistant strains.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Infectious Diseases
Xiaoyu Zhao, Shirong Li, Yixin Zhang, Jue Wang, Chuning Wang, Xiaohua Qin, Fupin Hu, Minggui Wang
Summary: This retrospective study evaluated the clinical efficacy of ceftazidime-avibactam (CZA) for the treatment of central nervous system (CNS) infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). The results showed that CZA-based combination therapy is an effective treatment option for CNS infections caused by CRKP.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
Yan Guo, Renru Han, Ge Zhang, Qiwen Yang, Feng Xue, Yun Li, Demei Zhu, Fupin Hu
Summary: The epidemiological cut-off values (TECOFFs) of contezolid for various Gram-positive bacteria such as Staphylococcus aureus, Enterococcus faecalis, Enterococcus faecium, Streptococcus pneumoniae, and Streptococcus agalactiae were determined based on MIC and zone diameter distributions.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2023)
Review
Immunology
Mei Zeng, Jun Xia, Zhiyong Zong, Yi Shi, Yuxing Ni, Fupin Hu, Yijian Chen, Chao Zhuo, Bijie Hu, Xiaoju Lv, Jiabin Li, Zhengyin Liu, Jing Zhang, Wenjie Yang, Fan Yang, Qiwen Yang, Hua Zhou, Xin Li, Jianhua Wang, Yimin Li, Jian'an Ren, Baiyi Chen, Dechang Chen, Anhua Wu, Xiangdong Guan, Jieming Qu, Depei Wu, Xiaojun Huang, Haibo Qiu, Yingchun Xu, Yunsong Yu, Minggui Wang
Summary: The dissemination of carbapenem-resistant Gram-negative bacilli is a global public health issue, as these bacteria are highly resistant and have limited treatment options, leading to high mortality rates. In order to address the clinical issues related to laboratory testing, antimicrobial therapy, and prevention of these infections, a multidisciplinary group of experts developed clinical practice guidelines based on the best available scientific evidence. These guidelines focus on carbapenem-resistant Enterobacteriales, carbapenem-resistant Acinetobacter baumannii, and carbapenem-resistant Pseudomonas aeruginosa.
JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION
(2023)
Article
Biochemistry & Molecular Biology
Xiaofen Liu, Chenrong Huang, Phillip J. Bergen, Jian Li, Jingjing Zhang, Yijian Chen, Yongchuan Chen, Beining Guo, Fupin Hu, Jinfang Hu, Linlin Hu, Xin Li, Hongqiang Qiu, Hua Shao, Tongwen Sun, Yu Wang, Ping Xu, Jing Yang, Yong Yang, Zhenwei Yu, Bikui Zhang, Huaijun Zhu, Xiaocong Zuo, Yi Zhang, Liyan Miao, Jing Zhang
Summary: Polymyxin B, a last-line antibiotic for extensively drug-resistant Gram-negative bacterial infections, was launched in China in Dec. 2017. Due to the lack of standardized dose adjustments, there is a need for therapeutic drug monitoring (TDM) to optimize its use. A consensus on TDM guidelines for polymyxin B, endorsed by medical associations and committees, has been released to provide recommendations on target concentrations, sample collection, reporting, and interpretation of TDM results. These guidelines aim to guide the optimal clinical use of polymyxin B.
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
(2023)
Article
Chemistry, Multidisciplinary
Zeyang Pang, Ning Ren, Yujie Wu, Jie Qi, Fupin Hu, Yuan Guo, Yangzhouyun Xie, Dejian Zhou, Xingyu Jiang
Summary: Bacterial keratitis is a serious ocular disease caused by Staphylococcus aureus, with a significant increase in methicillin-resistant strains leading to refractory keratitis. Atomically precise gold nanoclusters (GNCs) are emerging as promising antibacterial agents, but the role of GNC structure and capping ligands in controlling antibacterial properties is not well understood.
ADVANCED MATERIALS
(2023)
Article
Microbiology
Yuexia Jia, Wenwe Chen, Rongbin Tang, Jiangjiang Zhang, Xiaoyan Liu, Ruihua Dong, Fupin Hu, Xingyu Jiang
Summary: We propose a multi-armed chemical scaffold (MACS) for antibiotc screening, consisting of a core unit and three or four arms. Through studying the structure-activity relationship of multi-armed molecules (MAMs), we discover a class of multi-armed antibiotics (MAAs) that can selectively interact with Gram-positive bacteria and inhibit cell wall assembly. MAAs have excellent antibacterial activities against Gram-positive bacteria, including clinical multi-drug-resistant isolates. Our study provides a chemical scaffold and identifies eight antibacterial lead compounds for antibiotic development.
CELL HOST & MICROBE
(2023)
Letter
Infectious Diseases
Li Ding, Yan Guo, Fupin Hu
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Chemistry, Physical
Gaoqiang Chen, Huijie Liu, Qingyu Shi
Summary: This study proposes a computational methodology for predicting material bonding defects during friction stir welding (FSW) by evaluating the in-process thermal-mechanical condition. Several modeling methods are integrated to predict the defects, and the performance of the computational analysis is demonstrated using FSW of AA2024 as an example. It is found that the dynamic sticking (DS) model can predict the geometry of the rotating flow zone, and the butting interface tracking (BIT) analysis shows a significant orientation change that affects the bonding pressure. The interfacial temperature and pressure are analyzed for their roles in material bonding. Four bonding-quality indexes are tested to quantify the thermal-mechanical condition and determine the critical value for successful solid-state bonding (SSB).
Article
Chemistry, Physical
Gaoqiang Chen, Xin Liu, Junnan Qiao, Tianxiang Tang, Hua Zhang, Songling Xing, Gong Zhang, Qingyu Shi
Summary: This communication paper introduces an analytical model for thermal softening of aluminum alloys from room temperature to solidus temperature, showing favorable comparison with established models. The constants of the proposed model for nine typical engineering commercial aluminum alloys are presented in the study.
Review
Microbiology
Li Ding, Siquan Shen, Jing Chen, Zhen Tian, Qingyu Shi, Renru Han, Yan Guo, Fupin Hu
Summary: KPC variants pose a growing resistance to carbapenem antibiotics, posing challenges to the treatment of Enterobacterales infections. Over 150 KPC variants have been reported worldwide, with most new variants discovered in the past few years. Currently, there are no clear guidelines for the diagnosis and treatment of infections caused by KPC variants. The effectiveness of new antibiotic combinations on KPC variants remains poorly discussed.
CLINICAL MICROBIOLOGY REVIEWS
(2023)
Article
Microbiology
Xiangning Huang, Siquan Shen, Fan Chang, Xin Liu, Jinxi Yue, Ning Xie, Lin Yin, Fupin Hu, Daiwen Xiao
Summary: This study reports a ceftazidime-avibactam-resistant Klebsiella pneumoniae strain carrying a novel KPC variant, KPC-134. The isolate showed resistance to multiple antibiotics but sensitivity to certain others. Further experiments revealed that the resistance was primarily mediated by a plasmid carrying the bla(KPC-134) gene, which also harbored other common resistance genes.
MICROBIOLOGY SPECTRUM
(2023)